nevirapine has been researched along with Hepatitis C in 28 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 9.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
| "Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment." | 7.76 | Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010) |
| "The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 5.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
| "Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment." | 3.76 | Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010) |
| " Risk factors were higher baseline alanine aminotransferase levels, chronic hepatitis B or C virus infection, antiretroviral therapy-naive patients undergoing their first HAART regimen, recent start of a regimen of nevirapine or high-dose ritonavir, and female sex." | 3.71 | Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. ( Jurriaans, S; Lange, JM; Weel, J; Weverling, GJ; Wit, FW, 2002) |
| "Nevirapine (NVP) is an effective nonnucleoside reverse transcriptase inhibitor (NNRTI) of particular interest as it is often used in resource limited countries." | 1.40 | Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine. ( Janphen, K; Kumrapich, B; Praparattanapan, J; Roytrakul, S; Smith, DR; Supparatpinyo, K; Thongtan, T; Wongtrakul, J, 2014) |
| "Demographic, treatment and pregnancy related data were collected." | 1.38 | Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. ( Boer, K; de Wolf, F; Godfried, MH; Nellen, JF; Smit, C; Snijdewind, IJ; van der Ende, ME, 2012) |
| " The correlation between nevirapine concentrations, efficacy and hepatotoxicity suggests the benefit of dosage adjustment based on therapeutic drug monitoring among Chinese HIV-infected patients to optimize nevirapine containing antiretroviral therapy." | 1.37 | Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. ( Fu, Q; Han, Y; Kou, H; Li, T; Li, Y; Ma, Q; Qiu, Z; Wang, J; Ye, M; Zhu, Z; Zuo, L, 2011) |
| " Newer HAART regimens have less toxicity and better dosing characteristics than first-generation regimens, but it is not known whether they are associated with improved clinical outcomes." | 1.34 | Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. ( Crane, HM; Kitahata, MM; Van Rompaey, SE, 2007) |
| " Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP." | 1.33 | Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. ( Calvet, GA; Cruz, ML; D'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (50.00) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Hasan, M | 1 |
| Yunihastuti, E | 1 |
| Teguh H, K | 1 |
| Abdullah, M | 1 |
| Su, S | 1 |
| Fairley, CK | 1 |
| Sasadeusz, J | 1 |
| He, J | 1 |
| Wei, X | 1 |
| Zeng, H | 1 |
| Jing, J | 1 |
| Mao, L | 1 |
| Chen, X | 1 |
| Zhang, L | 1 |
| Torimiro, JN | 1 |
| Nanfack, A | 1 |
| Takang, W | 1 |
| Keou, CK | 1 |
| Joyce, AN | 1 |
| Njefi, K | 1 |
| Agyingi, K | 1 |
| Domkam, I | 1 |
| Takou, D | 1 |
| Moudourou, S | 1 |
| Sosso, S | 1 |
| Mbu, RE | 1 |
| Vispo, E | 1 |
| Fernández-Montero, JV | 1 |
| Labarga, P | 1 |
| Barreiro, P | 1 |
| Soriano, V | 1 |
| Cain, LE | 1 |
| Hernán, MA | 1 |
| van Griensven, J | 1 |
| Phirum, L | 1 |
| Choun, K | 1 |
| Thai, S | 1 |
| De Weggheleire, A | 1 |
| Lynen, L | 1 |
| Andreotti, M | 1 |
| Pirillo, MF | 1 |
| Liotta, G | 1 |
| Jere, H | 1 |
| Maulidi, M | 1 |
| Sagno, JB | 1 |
| Luhanga, R | 1 |
| Amici, R | 1 |
| Mancini, MG | 1 |
| Gennaro, E | 1 |
| Marazzi, MC | 1 |
| Vella, S | 1 |
| Giuliano, M | 1 |
| Palombi, L | 1 |
| Mancinelli, S | 1 |
| Wongtrakul, J | 1 |
| Thongtan, T | 1 |
| Roytrakul, S | 1 |
| Kumrapich, B | 1 |
| Janphen, K | 1 |
| Praparattanapan, J | 1 |
| Supparatpinyo, K | 1 |
| Smith, DR | 1 |
| Li, T | 2 |
| Dai, Y | 1 |
| Kuang, J | 1 |
| Jiang, J | 1 |
| Han, Y | 2 |
| Qiu, Z | 2 |
| Xie, J | 1 |
| Zuo, L | 2 |
| Li, Y | 2 |
| Mbougua, JB | 1 |
| Laurent, C | 1 |
| Kouanfack, C | 1 |
| Bourgeois, A | 1 |
| Ciaffi, L | 1 |
| Calmy, A | 1 |
| Gwet, H | 1 |
| Koulla-Shiro, S | 1 |
| Ducos, J | 1 |
| Mpoudi-Ngolé, E | 1 |
| Molinari, N | 1 |
| Delaporte, E | 1 |
| Wang, J | 1 |
| Kou, H | 1 |
| Fu, Q | 1 |
| Zhu, Z | 1 |
| Ye, M | 1 |
| Ma, Q | 1 |
| Rosso, R | 1 |
| Rossotti, R | 1 |
| Di Biagio, A | 1 |
| Nicolini, L | 1 |
| Adorni, F | 1 |
| Orani, A | 1 |
| Viscoli, C | 1 |
| Snijdewind, IJ | 1 |
| Smit, C | 1 |
| Godfried, MH | 1 |
| Nellen, JF | 1 |
| de Wolf, F | 1 |
| Boer, K | 1 |
| van der Ende, ME | 1 |
| Podzamczer, D | 2 |
| Tiraboschi, JM | 1 |
| Mallolas, J | 1 |
| Curto, J | 1 |
| Cárdenes, MA | 1 |
| Casas, E | 1 |
| Castro, A | 1 |
| Echevarría, S | 1 |
| Leal, M | 1 |
| Lopez Bernaldo de Quirós, JC | 1 |
| Moreno, S | 2 |
| Puig, T | 1 |
| Ribera, E | 1 |
| Villalonga, C | 1 |
| Gómez-Sirvent, JL | 1 |
| García-Henarejos, JA | 1 |
| Lopez-Aldeguer, J | 1 |
| Barrufet, P | 1 |
| Force, L | 1 |
| Santos, I | 1 |
| Sanz, J | 1 |
| Llibre, JM | 1 |
| Jackson, JB | 1 |
| Barnett, S | 1 |
| Piwowar-Manning, E | 1 |
| Apuzzo, L | 1 |
| Raines, C | 1 |
| Hendrix, C | 1 |
| Hamzeh, F | 1 |
| Gallant, J | 1 |
| Pulido, F | 1 |
| Torralba, M | 1 |
| Law, WP | 1 |
| Dore, GJ | 1 |
| Duncombe, CJ | 1 |
| Mahanontharit, A | 1 |
| Boyd, MA | 1 |
| Ruxrungtham, K | 1 |
| Lange, JM | 2 |
| Phanuphak, P | 1 |
| Cooper, DA | 1 |
| Almond, LM | 1 |
| Boffito, M | 1 |
| Hoggard, PG | 1 |
| Bonora, S | 1 |
| Raiteri, R | 1 |
| Reynolds, HE | 1 |
| Garazzino, S | 1 |
| Sinicco, A | 1 |
| Khoo, SH | 1 |
| Back, DJ | 1 |
| Di Perri, G | 1 |
| Aranzabal, L | 1 |
| Casado, JL | 1 |
| Moya, J | 1 |
| Quereda, C | 1 |
| Diz, S | 1 |
| Moreno, A | 2 |
| Moreno, L | 1 |
| Antela, A | 1 |
| Perez-Elias, MJ | 1 |
| Dronda, F | 1 |
| Marín, A | 1 |
| Hernandez-Ranz, F | 1 |
| João, EC | 1 |
| Calvet, GA | 1 |
| Menezes, JA | 1 |
| D'Ippolito, MM | 1 |
| Cruz, ML | 1 |
| Salgado, LA | 1 |
| Matos, HJ | 1 |
| Littera, R | 1 |
| Carcassi, C | 1 |
| Masala, A | 1 |
| Piano, P | 1 |
| Serra, P | 1 |
| Ortu, F | 1 |
| Corso, N | 1 |
| Casula, B | 1 |
| La Nasa, G | 1 |
| Contu, L | 1 |
| Manconi, PE | 1 |
| Torti, C | 1 |
| Costarelli, S | 1 |
| De Silvestri, A | 1 |
| Quiros-Roldan, E | 1 |
| Lapadula, G | 1 |
| Cologni, G | 1 |
| Paraninfo, G | 1 |
| Castelnuovo, F | 1 |
| Puoti, M | 1 |
| Carosi, G | 1 |
| Crane, HM | 1 |
| Van Rompaey, SE | 1 |
| Kitahata, MM | 1 |
| Berenguer, J | 1 |
| Bellón, JM | 1 |
| Miralles, P | 1 |
| Alvarez, E | 1 |
| Castillo, I | 1 |
| Cosín, J | 1 |
| López, JC | 1 |
| Sánchez Conde, M | 1 |
| Padilla, B | 1 |
| Resino, S | 1 |
| Sulkowski, MS | 1 |
| Thomas, DL | 1 |
| Mehta, SH | 1 |
| Chaisson, RE | 1 |
| Moore, RD | 1 |
| Wit, FW | 1 |
| Weverling, GJ | 1 |
| Weel, J | 1 |
| Jurriaans, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00618176] | Phase 4 | 198 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols[NCT00411983] | 10,000 participants (Anticipated) | Observational | 2002-11-30 | Recruiting | |||
| Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.[NCT01908660] | 192 participants (Actual) | Observational [Patient Registry] | 2007-01-31 | Completed | |||
| Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV[NCT00051090] | 0 participants (Actual) | Interventional | Withdrawn | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nevirapine and Hepatitis C
| Article | Year |
|---|---|
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepat | 2002 |
2 trials available for nevirapine and Hepatitis C
| Article | Year |
|---|---|
Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Asian People; CD4 Lymphocyte | 2008 |
A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis C; HIV Infection | 2003 |
25 other studies available for nevirapine and Hepatitis C
| Article | Year |
|---|---|
Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Exanthema; | 2022 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce | 2018 |
Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cameroon; Coinfection; Drug Resistance, Viral; F | 2018 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug | 2013 |
The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Llibre and Podzamczer and additional results.
Topics: Anti-HIV Agents; Benzoxazines; Hepatitis C; HIV Infections; Humans; Nevirapine; Reverse Transcriptas | 2013 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; C | 2014 |
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He | 2014 |
Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
Topics: Alanine Transaminase; Anti-HIV Agents; Biomarkers; Blood Proteins; Chemical and Drug Induced Liver I | 2014 |
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coho | 2010 |
Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.
Topics: Adult; Asian People; CD4 Lymphocyte Count; China; Clinical Trials as Topic; Demography; Female; Hepa | 2011 |
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Databa | 2011 |
Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Drug Th | 2012 |
Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studi | 2012 |
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Dose-Respo | 2012 |
Nevirapine levels may predict toxicity.
Topics: Hepatitis C; HIV Infections; Humans; Liver Function Tests; Nevirapine; Reverse Transcriptase Inhibit | 2002 |
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclop | 2003 |
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
Topics: Alanine Transaminase; Anti-HIV Agents; Cross-Sectional Studies; Ethnicity; Female; gamma-Glutamyltra | 2004 |
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and D | 2005 |
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholestasis; Cohort Studies; Female; Hepatitis B; Hepa | 2006 |
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
Topics: Adolescent; Adult; Drug Hypersensitivity; Female; Gene Frequency; Haplotypes; Hepatitis C; Histocomp | 2006 |
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; CD4 Lymphocyte Count; Che | 2007 |
Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Hepatitis C; HIV Infections; HIV Protease Inhi | 2007 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progr | 2008 |
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspart | 2002 |
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Dr | 2002 |